YBGJOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Yubo International Biotech Ltd

Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.01+0.00 (0.00%)

Close on Oct 16, 2026

Market cap: $886.19K
P/E (TTM): –
Dividend yield: –

Yubo International Biotech Ltd cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2025-12-31	FY 2025 2024-12-31	FY 2024 2023-12-31	FY 2023 2022-12-31	FY 2022 2021-12-31	FY 2020 2020-02-29	FY 2019 2019-02-28	FY 2018 2018-02-28	FY 2017 2017-02-28	FY 2016 2016-02-29	FY 2015 2015-02-28	FY 2014 2014-02-28	FY 2013 2013-02-28	FY 2012 2012-02-29	FY 2011 2011-02-28
Depreciation & Amortization	0.17	0.17	0.18	0.02	0.01	–	–	–	–	–	–	–	–	–	–
Change in Accounts Receivable	0.03	-0.09	-0.03	-0.11	-0.16	–	–	–	–	–	–	–	–	–	–
Change in Inventory	0.01	0.18	0.11	0.16	-0.10	–	–	–	–	–	–	–	–	–	–
Change in Accounts Payable	0.02	0.21	0.28	0.27	0.17	0.11	0.12	0.09	0.17	0.07	0.05	0.06	0.07	0.04	0.06
Operating Cash Flow	-0.84	-1.34	-0.74	-0.60	-1.02	-0.02	-0.03	-0.06	-0.06	-0.06	-0.06	-0.05	-0.04	-0.04	-0.05
Capital Expenditures	–	–	–	0	-0.56	–	–	–	–	–	–	–	–	–	–
Sale of Property, Plant & Equipment	0	0.12	–	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	0	0.12	0	-0.04	-0.56	0	0	0	0	–	–	–	–	–	–
Financing Cash Flow	0.85	1.41	0.75	0.67	0.13	0.02	0.03	0.06	0.05	0.06	–	–	–	–	–
Foreign Exchange Rate Adjustments	-0.01	-0.19	-0.02	-0.04	0.10	–	–	–	–	–	–	–	–	–	–
Net Change in Cash	0.00	0.00	-0.01	-0.01	-1.36	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.01	0	0.00
Free Cash Flow	–	–	–	-0.60	-1.59	–	–	–	–	–	–	–	–	–	–
Income Taxes Paid	0	0	0	0	0	0	0	–	–	–	–	–	–	–	–
Interest Paid	0	0	0	0	0	0	0	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 66.1%
Operating margin: -9096.9%
Net margin: -8157.3%
Return on equity, FY2026: 40.1%

Financial strength

Current ratio: 0.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.4%

Valuation

P/E ratio: –
Price to sales: 71.74
Price to book: –
Dividend yield: –